Analysts think PLUR stock price could decrease by -26%
Jun 14, 2024, 6:28 AM
-13.36%
What does PLUR do
Pluri, Inc. is a clinical-stage biotechnology company focused on developing cell therapies, specifically PLX-PAD and PLX R18, for conditions like critical limb ischemia and acute radiation syndrome. Their research involves expanding placental-derived stromal cells using a synthetic scaffold-based 3D process, with products administered via standard injection.
3 analysts think PLUR stock price will decrease by -26.35%. The current median analyst target is $4.08 compared to a current stock price of $5.54. The lowest analysts target is $4.04 and the highest analyst target is $4.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.